Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation (NICE - SUGAR STUDY)

This study has been completed.
Australian and New Zealand Intensive Care Society Clinical Trials Group
Canadian Critical Care Trials Group
National Health and Medical Research Council, Australia
Health Research Council, New Zealand
University of British Columbia
Information provided by:
The George Institute Identifier:
First received: September 13, 2005
Last updated: January 27, 2009
Last verified: January 2009
The primary aim of the study is to compare the effects of the two blood glucose targets on 90 day all-cause mortality in Intensive Care patients who are predicted on admission to stay in the ICU for at least one full calendar day. The hypothesis is that there is little difference in the relative risk of death between patients assigned a glucose range of 4.5 - 6.0 mmol/L, and those assigned a glucose range of less than 10.0 mmol/L with insulin being infused if blood glucose exceeds 10.0 mmol/L, and adjusted when needed to maintain blood glucose of 8.0 - 10.0 mmol/L.

Condition Intervention Phase
Critical Illness
Other: Intensive Insulin Therapy
Other: Conventional Insulin therapy
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-Center, Open Label Randomized Stratified Controlled Trial of the Effects of Blood Glucose Management on 90-Day All-Cause Mortality in a Heterogenous Population of Intensive Care Unit (ICU) Patients.

Resource links provided by NLM:

Further study details as provided by The George Institute:

Primary Outcome Measures:
  • all-cause mortality [ Time Frame: 90 days ]

Secondary Outcome Measures:
  • The secondary outcomes, also determined over the same period of 90 days include: [ Time Frame: 90 days ]
  • All cause mortality [ Time Frame: Day 28 ]
  • Length of intensive care unit stay; [ Time Frame: 90 days ]
  • Length of hospital stay; [ Time Frame: 90 Days ]
  • The need for organ support (inotropes, renal replacement therapy and positive pressure ventilation); [ Time Frame: 90 Days ]
  • Incidence of blood stream infections; [ Time Frame: 90 Days ]
  • Incidence and severity of hypoglycaemia; [ Time Frame: 90 Days ]
  • extended glasgow outcome score [ Time Frame: 2 years ]

Enrollment: 6104
Study Start Date: April 2005
Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intensive Insulin therapy
Intensive Insulin therapy
Other: Intensive Insulin Therapy
Maintain blood glucose 4.5 - 6.o mmol/L
Active Comparator: Conventional Therapy
conventional insulin therapy
Other: Conventional Insulin therapy
Maintain blood glucose 8-10mmol/L

  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients are eligible for INCLUSION in the study if ALL the following criteria are met:

    1. At time of the patient's admission to the ICU the treating ICU specialist expects the patient will require treatment in the ICU that extends beyond the calendar day following the day of admission.
    2. Patient has an arterial line in situ or placement of an arterial line is imminent (within the next hour) as part of routine ICU management.

Exclusion Criteria:

Patients will be EXCLUDED from the study if ONE or MORE of the following criteria are present:

  1. Age < 18 years.
  2. Imminent death (cardiac standstill or brain death anticipated in less than 24 hours) and the treating clinicians are not committed to full supportive care. This should be confirmed by a documented treatment-limitation order that exceeds a "not-for-resuscitation" order.
  3. Patients admitted to the ICU for treatment of diabetic ketoacidosis or hyperosmolar state.
  4. Patient is expected to be eating before the end of the day following admission
  5. Patients who have suffered hypoglycaemia without documented full neurological recovery.
  6. Patient thought to be at abnormally high risk of suffering hypoglycaemia ( e.g. known insulin secreting tumour or history of unexplained or recurrent hypoglycaemia or fulminant hepatic failure)
  7. If a patient has previously been enrolled in the NICE-SUGAR Study (patients cannot be enrolled in the NICE-SUGAR Study more than once).
  8. If the patient can not provide prior informed consent, there is documented evidence that the patient has no legal surrogate decision maker and it appears unlikely that the patient will regain consciousness or sufficient ability to provide delayed informed consent
  9. The patient has been in the study ICU or another ICU for longer than 24 hours for this admission.

There is no upper age limit for inclusion into the study unless any of the specific exclusion criteria are present.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00220987

Australia, New South Wales
The George Institute for International Health
Camperdown, New South Wales, Australia, 2050
Sponsors and Collaborators
The George Institute
Australian and New Zealand Intensive Care Society Clinical Trials Group
Canadian Critical Care Trials Group
National Health and Medical Research Council, Australia
Health Research Council, New Zealand
University of British Columbia
Study Chair: Simon Finfer, MBBS Royal North Shore Hospital
Principal Investigator: John Myburgh, MBBS St. George Hospital, Sydney
Principal Investigator: Rinaldo Bellomo, MBBS Austin Hospital, Melbourne Australia
Principal Investigator: Imogen Mitchell, MBBS The Canberra Hospital, ACT
Principal Investigator: Colin McArthur, MBBS Auckland Hospital, New Zealand
Principal Investigator: Robyn Norton, Prof. The George Institute
Principal Investigator: Suzanne McEvoy, MBBS The George Institute
Principal Investigator: Leonie J Crampton, RN; CNS The George Institute
Principal Investigator: Julie Potter, RN Royal North Shore Hospital
Principal Investigator: Vinay Dhingra, MBBS Vancouver General Hospital
Principal Investigator: Deborah Cook, MBBS St. Joseph's Hospital, Ontario
Principal Investigator: Paul Hebert, MBBS The Ottawa Hospital
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Simon Finfer, The George Institute Identifier: NCT00220987     History of Changes
Obsolete Identifiers: NCT00175331
Other Study ID Numbers: GI-IAT-NIC-G
NHMRC GRANT - 293201
Study First Received: September 13, 2005
Last Updated: January 27, 2009

Keywords provided by The George Institute:
Hyperglycemia in the critically ill patient
Intensive Insulin Therapy
Conventional insulin therapy

Additional relevant MeSH terms:
Critical Illness
Glucose Metabolism Disorders
Metabolic Diseases
Disease Attributes
Pathologic Processes
Insulin, Globin Zinc
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on April 28, 2017